4th Congress on Controversies in Thrombosis and Hemostasis (CiTH) 2017

The 4th Congress on Controversies in Thrombosis and Hemostasis (CiTH) 2017 is dedicated to unresolved clinical, therapeutic dilemmas and clinical solutions related to Thrombosis and Hemostasis, including:

• Bleeding disorders
  • The role of thrombopoietics in ITP
  • Plasma derived vs. recombinant factor VIII concentrate
  • Replacement therapy before surgery of factor XI & factor VII deficient patient
• Thrombotic disorders & antithrombotics
  • Role of thrombophilia in gestation complication
  • Thrombophilia screen
  • Warfarin in the next 10 years
  • Heparins in the next 10 years
  • Direct thrombin inhibitors and factor Xa inhibitors
  • Direct thrombin inhibitors and factor Xa inhibitors
  • New antiplatelet agents
  • Should we monitor anti platelet therapy
  • The role of catheter guided thrombolysis in DVT
  • Pharmacogenomics
  • Primary prevention of coronary heart disease by ASA
  • Extended VTE prophylaxis in medically ill patients
• Pediatrics
  • Is there a role for primary antocoagulants prolphylaxis in children with ALL
  • Should infants with perinatal thrombosis be screened for thrombophilia and treated by antocoagulants
  • Should we screen children for coagulopathies prior to surgery?
  • Prophylaxis for children with hemophilia should start early or after joint bleed? Is low dose regimen preferable to standard dose?